Swiss Life Sciences Stock News

If you are wondering whether UBS Group is fairly priced or offering value right now, looking closely at its current valuation can help you decide how it might fit into your portfolio. The share price closed at CHF 30.13, with returns of 2.8% decline over 7 days, 11.4% decline over 30 days, a 21.1% decline year to date, a 10.8% gain over 1 year, and a very large gain over 5 years. Recent news around UBS Group has focused on its role as a major Swiss-based global bank and wealth manager...

Sensirion Holding (SWX:SENS) has reported fresh FY 2025 numbers, with first half revenue at CHF 184.547 million and basic EPS of CHF 0.67, while trailing twelve month revenue stands at CHF 333.076 million and basic EPS at CHF 1.126105. The company has seen revenue move from CHF 127.972 million with basic EPS of CHF 2.31 in the first half of 2024 to CHF 148.529 million with basic EPS of CHF 0.45638 in the second half of 2024. This has set up the current CHF 184.547 million revenue and CHF 0.67...

Cosmo Pharmaceuticals (SWX:COPN) has just released its full year 2025 results, highlighting higher recurring revenues, a proposed €2.10 dividend per share, and management’s outlook for recurring revenue and EBITDA growth in 2026. See our latest analysis for Cosmo Pharmaceuticals. That earnings release came after a sharp pullback, with a 1 day share price return of a 5.25% decline and a 30 day share price return of a 19.74% decline. However, the 1 year total shareholder return of 82.16% still...

Partners Group Holding (SWX:PGHN) opened FY 2025 with first half revenue of CHF 1.2b and basic EPS of CHF 22.24, setting the tone for another data rich year of results. The company has seen revenue move from CHF 964.3m in the first half of 2024 to CHF 1.15b in the second half of 2024 and then to CHF 1.16b in the first half of 2025, while basic EPS shifted from CHF 19.52 to CHF 23.89 and then to CHF 22.24 over the same periods. With trailing net profit margins described at 49.2% compared with...

BKW (SWX:BKW) is back in focus after reporting a 40% drop in net profit tied to an extraordinary value adjustment on its German coal plant, while at the same time raising its dividend. See our latest analysis for BKW. At a share price of CHF149.0, BKW has a 90 day share price return of a 10.08% decline and a year to date share price return of a 13.87% decline. The 5 year total shareholder return of 54.09% points to stronger longer term compounding despite recent pressure, suggesting sentiment...

Flughafen Zürich (SWX:FHZN) has wrapped up FY 2025 with second half revenue of CHF 720.4 million, basic EPS of CHF 6.03 and net income of CHF 185.2 million, supported by trailing twelve month revenue of about CHF 1.4 billion and EPS of CHF 11.29. The company has seen revenue move from CHF 695.2 million in the second half of 2024 to CHF 720.4 million in the second half of 2025, while trailing twelve month EPS has shifted from CHF 10.64 to CHF 11.29. This gives investors a cleaner view on how...

What Implenia’s latest annual results mean for shareholders Implenia (SWX:IMPN) released its full year 2025 earnings, with sales of CHF 3,474.55 million and net income of CHF 83.64 million, both lower than the previous year, prompting fresh attention on the stock. See our latest analysis for Implenia. The earnings release appears to have reset expectations, with the share price at CHF73.50 and a 1 day share price return of 4.7% and a 90 day share price return of 7.9%. The 1 year total...

Avolta (SWX:AVOL) has drawn fresh attention after releasing full year 2025 results, reporting CHF 13,983 million in revenue and CHF 199 million in net income, along with higher earnings per share compared with the prior year. See our latest analysis for Avolta. The latest earnings release appears to have given Avolta’s share price a short term lift, with a 1 day share price return of 2.87% to CHF45.84. However, the 30 day share price return of a 7.21% decline suggests momentum has cooled,...

Roche Holding's oral SERD breast cancer candidate giredestrant did not meet the primary endpoint of progression free survival in the Phase III persevERA trial. The result affects expectations for one of Roche’s key late stage oncology assets and raises questions about the future shape of its pharma pipeline. Roche has indicated it will continue other giredestrant studies, while the market reassesses the commercial potential of the drug. For investors watching SWX:ROG, this clinical setback...

Sika (SWX:SIKA) has drawn fresh attention after announcing a commercial partnership with Giatec Scientific to integrate AI driven concrete sensors and software into its global product range for producers worldwide. See our latest analysis for Sika. That partnership news lands against a tougher backdrop, with Sika’s share price at CHF140.9 and a 30 day share price return showing a 9.68% decline, while the 1 year total shareholder return of 37.07% decline points to pressure that predates this...

Clariant (SWX:CLN) is back in focus after its 2025 results showed sales of CHF 3,915 million, compared with CHF 4,152 million a year earlier, alongside a net loss instead of prior net income. See our latest analysis for Clariant. The latest CHF7.55 share price reflects mixed sentiment, with a 1 day share price return of 2.58% but a 1 year total shareholder return decline of 22.32% and a 5 year total shareholder return decline of 53.98%. This suggests that longer term momentum has been weak...

SIG Group (SWX:SIGN) is back in focus after its latest full year results showed sales of €3,248.7 million and a shift from €194.5 million net income to a €87 million net loss. See our latest analysis for SIG Group. The earnings release has come after a mixed stretch for the stock, with a 90 day share price return of 25.65% and a 1 year total shareholder return decline of 31.77%. This suggests recent momentum has improved while longer term returns remain weak as investors reassess the risk...

Sulzer (SWX:SUN) has drawn fresh attention after reporting full year 2025 earnings, alongside an annual dividend of CHF 4.75 per share with payment set for April 21, 2026. See our latest analysis for Sulzer. The dividend and earnings update comes after a mixed stretch for Sulzer’s share price, with a 5.16% 1 day share price return and a 14.95% 90 day share price return contrasting with a 7.39% 30 day share price decline. Over longer periods, the 3 year total shareholder return of 137.95% and...

UBS Group increased its bonus pool by 10% as it moves closer to completing the integration of Credit Suisse. Management pay structures and division level performance, particularly in investment banking, are drawing attention to how the combined group is being run. The changes highlight how UBS is rewarding staff and shaping its culture after the acquisition of Credit Suisse. UBS Group (SWX:UBSG) is in focus as it reshapes incentives around the Credit Suisse integration, with the current...

Komax Holding (SWX:KOMN) has opened FY 2025 with first half revenue of CHF 278.3 million and a basic EPS loss of CHF 0.68, while trailing twelve month revenue sits at CHF 580.9 million against a basic EPS loss of CHF 1.77. Over the recent reporting periods, the company has seen revenue move from CHF 319.2 million in 1H 2024 to CHF 299.9 million in 2H 2024 and then to CHF 278.3 million in 1H 2025. EPS shifted from a profit of CHF 0.49 in 1H 2024 to losses of CHF 1.12 and CHF 0.68 in the...

Earnings and Dividend Decisions Put Kuehne + Nagel International in Focus Kuehne + Nagel International (SWX:KNIN) is back on investors’ radar after reporting full year 2025 results that included lower sales, softer earnings and a reduced annual dividend per share. See our latest analysis for Kuehne + Nagel International. The earnings miss and lower dividend appear to have weighed on sentiment, with the share price at CHF172.15 and a 1 year total shareholder return of 14.5% decline, while the...

Kuros Biosciences (SWX:KURN) is in focus after reporting 72% year over year sales growth to US$146.1 million for 2025, its first net profit, and issuing upbeat multi year sales guidance. See our latest analysis for Kuros Biosciences. The recent guidance for at least 35% annual sales growth through 2028, alongside FDA clearance for the MagnetOs MIS Delivery System and construction of a new U.S. plant, helps explain why the share price has a 1 month share price return of 16.57% and a 1 year...

Swiss Re (SWX:SREN) is back in the spotlight after reporting full year 2025 net income of US$4.74b, confirming 2026 guidance of US$4.5b, proposing a 9% higher dividend, and unveiling a sizeable buyback program. See our latest analysis for Swiss Re. The mix of higher 2025 net income, confirmed 2026 guidance, a 9% dividend uplift and a sizeable buyback has arrived while Swiss Re’s share price return this year has been slightly negative, even though the 3 year and 5 year total shareholder...

If you have been wondering whether Roche Holding shares are now offering good value or pricing in a lot of optimism, you are not alone. The stock last closed at CHF 332.40, with a 7 day return of an 8.4% decline, a 30 day return of a 6.7% decline, a 1 year return of 11.7% and a 3 year return of 40.4%. Recent moves in the share price sit against ongoing attention on Roche Holding as a major healthcare group, including continuing focus on its pharmaceuticals and diagnostics businesses and...

Ascom Holding (SWX:ASCN) has posted its FY 2025 first half results with revenue of CHF140 million, basic EPS of CHF0.06 and net income of CHF2.2 million, giving investors a fresh read on how the business is tracking this year. The company has seen revenue move from CHF142.1 million with EPS of CHF0.08 and net income of CHF2.9 million in 1H 2024 to CHF144.6 million with EPS of roughly CHF0.02 and net income of CHF0.8 million in 2H 2024, before landing at the current 1H 2025 run rate, so the...

Cosmo Pharmaceuticals (SWX:COPN) has kicked off FY 2025 with first half revenue of €51.7 million and a basic EPS loss of €0.13, following FY 2024 second half revenue of €130.6 million with basic EPS of €3.45 and first half 2024 revenue of €136.2 million with basic EPS of €4.42. Over the trailing twelve months in the data, revenue is €182.3 million with basic EPS of €3.68. Investors may focus on how the latest dip into a small loss fits against a period where margins and earnings have...

Earnings event and what changed Walliser Kantonalbank (SWX:WKBN) has released full year 2025 results, with net interest income of CHF 195.3 million and net income of CHF 85.87 million, both lower than the previous year. For you as an investor, the key question is how these earnings shifts affect the appeal of a regional Swiss bank that offers a broad mix of retail, lending, and wealth management services, all denominated in CHF. See our latest analysis for Walliser Kantonalbank. The share...

Why Galderma’s latest results matter for shareholders Galderma Group (SWX:GALD) just reported record full year 2025 figures, with net sales of US$5,207 million and net income of US$613 million, and paired that with fresh 2026 guidance and product milestones. For investors, the combination of earnings, a completed share buyback and detailed growth expectations provides new information about how management is running the business and prioritising capital allocation. See our latest analysis for...

Why the Bichsel decision matters for Galenica shareholders Galenica (SWX:GALE) has launched a consultation process on a planned production closure at its Bichsel subsidiary, a move that could affect up to 170 jobs by the end of 2026. The company plans to support affected employees with financial assistance, career guidance, and potential alternative roles within the wider Galenica network. A final decision is expected after the consultation concludes in mid March 2026. See our latest analysis...